ARTHUR G JAMES CANCER HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $9.4M
- Transactions
- 859
- Companies
- 27
- Average per transaction
- $10,968
Who reported the payments
| Pfizer | $2,503,114 |
| Merck | $2,140,138 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,892,583 |
| Novartis | $939,463 |
| Plexxikon Inc. | $374,692 |
| National Marrow Donor Program | $331,269 |
| AbbVie | $305,980 |
| E.r. Squibb & Sons, L.L.C. | $259,891 |
| Syndax Pharmaceuticals, Inc. | $203,783 |
| Bristol Myers Squibb | $128,831 |
| Biofire Diagnostics, LLC | $105,590 |
| Clovis Oncology, Inc. | $59,954 |
| Monteris Medical Corporation | $57,500 |
| Pharmacyclics LLC, An Abbvie Company | $45,379 |
| Incyte Corporation | $26,737 |
| Seagen Inc. | $16,193 |
| C. R. Bard, Inc. & Subsidiaries | $9,080 |
| Elekta Instrument AB | $6,500 |
| Acclarent, Inc | $5,358 |
| Verastem, Inc. | $4,059 |
| AstraZeneca | $1,525 |
| Eisai Inc. | $1,250 |
| Stryker | $848 |
| Springworks Therapeutics, Inc. | $750 |
| Linvatec Corporation | $513 |
| Daiichi Sankyo Inc. | $313 |
| Urogen Pharma, Inc. | $125 |